Latest Breaking News On - Brookline capital markets - Page 1 : comparemela.com

FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder - X4 Pharmaceuticals (NASDAQ:XFOR)

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

DT Cloud Acquisition Corporation Announces Upcoming Automatic Unit Separation

New York, New York, April 10, 2024 (GLOBE NEWSWIRE) DT Cloud Acquisition Corporation (Nasdaq: DYCQU) (the “Company”) announced today that, co.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

WARREN, N.J., March 25, 2024 Aquestive Therapeutics, Inc. , a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and.

DT Cloud Acquisition Corporation Announces Closing of $69 Million Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

DT Cloud Acquisition Corporation Announces Closing of $69 Million Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option